DK1056722T3 - Hydrogensulfatsalt af HIV-protease-inhibitor - Google Patents
Hydrogensulfatsalt af HIV-protease-inhibitorInfo
- Publication number
- DK1056722T3 DK1056722T3 DK98964878T DK98964878T DK1056722T3 DK 1056722 T3 DK1056722 T3 DK 1056722T3 DK 98964878 T DK98964878 T DK 98964878T DK 98964878 T DK98964878 T DK 98964878T DK 1056722 T3 DK1056722 T3 DK 1056722T3
- Authority
- DK
- Denmark
- Prior art keywords
- protease inhibitor
- hydrogen sulfate
- hiv protease
- sulfate salt
- hiv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7196898P | 1998-01-20 | 1998-01-20 | |
| PCT/US1998/027382 WO1999036404A1 (en) | 1998-01-20 | 1998-12-22 | Bisulfate salt of hiv protease inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1056722T3 true DK1056722T3 (da) | 2002-09-30 |
Family
ID=22104737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98964878T DK1056722T3 (da) | 1998-01-20 | 1998-12-22 | Hydrogensulfatsalt af HIV-protease-inhibitor |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US6087383A (da) |
| EP (1) | EP1056722B1 (da) |
| JP (2) | JP4860037B2 (da) |
| KR (1) | KR100559283B1 (da) |
| CN (1) | CN1116282C (da) |
| AR (1) | AR014417A1 (da) |
| AT (1) | ATE219057T1 (da) |
| AU (1) | AU735875B2 (da) |
| BG (1) | BG64774B1 (da) |
| BR (1) | BR9814736A (da) |
| CA (1) | CA2317736C (da) |
| CO (1) | CO4970820A1 (da) |
| CZ (1) | CZ293507B6 (da) |
| DE (1) | DE69806067T2 (da) |
| DK (1) | DK1056722T3 (da) |
| EE (1) | EE04434B1 (da) |
| EG (1) | EG23936A (da) |
| ES (1) | ES2178300T3 (da) |
| GE (1) | GEP20033026B (da) |
| HK (2) | HK1033667A1 (da) |
| HU (1) | HU227196B1 (da) |
| IL (2) | IL137384A0 (da) |
| LT (1) | LT4780B (da) |
| LV (1) | LV12522B (da) |
| MY (1) | MY114838A (da) |
| NO (1) | NO315605B1 (da) |
| NZ (1) | NZ504417A (da) |
| PE (1) | PE20000185A1 (da) |
| PL (1) | PL190744B1 (da) |
| PT (1) | PT1056722E (da) |
| RO (1) | RO118869B1 (da) |
| RU (1) | RU2186070C2 (da) |
| SK (1) | SK283975B6 (da) |
| TR (1) | TR200001876T2 (da) |
| TW (1) | TW531531B (da) |
| UA (1) | UA59432C2 (da) |
| UY (1) | UY25345A1 (da) |
| WO (1) | WO1999036404A1 (da) |
| ZA (1) | ZA9956B (da) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2448084A1 (en) * | 2001-05-22 | 2002-11-28 | Elan Pharmaceuticals, Inc. | Aza hydroxylated ethyl amine compounds |
| US7193065B2 (en) * | 2001-07-13 | 2007-03-20 | Roche Diagnostics Operations, Inc. | Protease inhibitor conjugates and antibodies useful in immunoassay |
| US7157561B2 (en) * | 2001-07-13 | 2007-01-02 | Roche Diagnostics Operations, Inc. | Methods of inhibiting transmission of a costimulatory signal of lymphocytes |
| AU2004206827A1 (en) * | 2003-01-14 | 2004-08-05 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
| CN1980666B (zh) * | 2004-05-04 | 2011-03-30 | 布里斯托尔-迈尔斯斯奎布公司 | 制备阿扎那韦硫酸氢盐的方法和新的形式 |
| US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
| US20050288343A1 (en) * | 2004-05-19 | 2005-12-29 | Andrew Rusowicz | Process of preparing substituted carbamates and intermediates thereof |
| TWI354569B (en) * | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| US7642049B2 (en) | 2006-06-30 | 2010-01-05 | Bristol-Myers Squibb Company | Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms |
| WO2008011117A2 (en) * | 2006-07-21 | 2008-01-24 | Gilead Sciences, Inc. | Antiviral protease inhibitors |
| BG66056B1 (bg) * | 2006-10-05 | 2010-12-30 | Красимир ДЕЧЕВ | Метод и инсталация за производство на трисезонна добавка към дизелово гориво |
| US20090036357A1 (en) * | 2007-06-12 | 2009-02-05 | Concert Pharmaceuticals, Inc. | Azapeptide derivatives |
| DE602008005462D1 (de) * | 2007-06-22 | 2011-04-21 | Bristol Myers Squibb Co | Tablettierte atazanavirhaltige zusammensetzungen |
| AU2008268627A1 (en) * | 2007-06-22 | 2008-12-31 | Bristol-Myers Squibb Company | Tableted compositions containing atazanavir |
| PL2178513T3 (pl) * | 2007-06-22 | 2011-09-30 | Bristol Myers Squibb Holdings Ireland | Kompozycje w tabletkach zawierające atazanawir |
| KR101686243B1 (ko) * | 2007-06-22 | 2016-12-13 | 브리스톨-마이어스 스퀴브 홀딩스 아일랜드 | 아타자나비르를 함유하는 정제 조성물 |
| AP2490A (en) * | 2007-06-29 | 2012-10-04 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
| BRPI0813000A2 (pt) * | 2007-06-29 | 2014-12-23 | Gilead Sciences Inc | Composições terapêuticas e uso das mesmas |
| WO2009136365A1 (en) * | 2008-05-08 | 2009-11-12 | Ranbaxy Laboratories Limited | Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof |
| WO2010070611A1 (en) | 2008-12-18 | 2010-06-24 | Ranbaxy Laboratories Limited | Atazanavir formulations |
| US8552036B2 (en) | 2009-01-12 | 2013-10-08 | Hetero Research Foundation | Polymorph of atazanavir sulfate |
| EP2435037B1 (en) | 2009-05-27 | 2014-11-12 | Merck Sharp & Dohme Corp. | Hiv protease inhibitors |
| EP2272830A1 (en) | 2009-06-18 | 2011-01-12 | Esteve Química, S.A. | Preparation process of an antivirally heterocyclic azahexane derivative |
| WO2011027324A1 (en) | 2009-09-03 | 2011-03-10 | Ranbaxy Laboratories Limited | Polymorphic forms of atazanavir sulfate |
| EP2493312B1 (en) | 2009-10-26 | 2021-10-20 | Merck Sharp & Dohme Corp. | Solid pharmaceutical compositions containing an integrase inhibitor |
| WO2011080562A1 (en) | 2009-12-29 | 2011-07-07 | Hetero Research Foundation | Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals |
| AU2011209788C1 (en) | 2010-01-27 | 2014-08-28 | Viiv Healthcare Company | Antiviral therapy |
| WO2011107843A2 (en) | 2010-03-01 | 2011-09-09 | Lupin Limited | Process for the preparation of atazanavir sulfate substantially free of diastereomers |
| CN102917695A (zh) | 2010-04-09 | 2013-02-06 | 百时美施贵宝公司 | 具有改进的pH效应的阿扎那韦硫酸盐制剂 |
| CA2849546A1 (en) | 2010-09-28 | 2012-04-05 | Ratiopharm Gmbh | Dry processing of atazanavir |
| WO2013014633A1 (en) | 2011-07-27 | 2013-01-31 | Ranbaxy Laboratories Limited | Process for preparation of atazanavir or its bisulfate salt |
| US8461347B2 (en) | 2011-08-05 | 2013-06-11 | Scinopharm Taiwan, Ltd. | Process for preparing form A of atazanavir sulfate |
| EP2771332B1 (en) | 2011-10-26 | 2016-06-29 | Merck Canada Inc. | Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS |
| EP2888230A4 (en) | 2012-08-24 | 2017-07-19 | Laurus Labs Private Limited | Improved process for the preparation of atazanavir bisulfate |
| WO2014036690A1 (zh) * | 2012-09-04 | 2014-03-13 | 上海迪赛诺化学制药有限公司 | 制备阿扎那韦硫酸氢盐a型结晶的方法 |
| EP2956439B1 (en) | 2013-02-12 | 2019-01-09 | Cipla Limited | Process for preparing atazanavir sulphate |
| CN104250224A (zh) * | 2013-06-28 | 2014-12-31 | 上海威智医药科技有限公司 | 阿扎那韦富马酸盐及其制备和应用 |
| CN104250225A (zh) * | 2013-06-28 | 2014-12-31 | 上海威智医药科技有限公司 | 阿扎那韦磷酸盐及其制备和应用 |
| CN104250223B (zh) * | 2013-06-28 | 2017-04-12 | 上海威智医药科技有限公司 | 阿扎那韦氢溴酸盐及其制备和应用 |
| CN105859611A (zh) * | 2016-04-18 | 2016-08-17 | 上海现代制药海门有限公司 | 一种阿扎那韦硫酸氢盐a型结晶的制备方法 |
| CN109251165B (zh) * | 2018-10-02 | 2022-09-23 | 国药集团川抗制药有限公司 | 阿扎那韦达二4-氨基苯磺酸盐及其制备方法 |
| CN111349042B (zh) * | 2018-12-20 | 2023-07-14 | 陕西理工大学 | 一种阿扎那韦单晶及其制备方法 |
| US12083099B2 (en) | 2020-10-28 | 2024-09-10 | Accencio LLC | Methods of treating symptoms of coronavirus infection with viral protease inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW409125B (en) * | 1996-04-22 | 2000-10-21 | Novartis Ag | Antivirally active heterocyclic azahexane derivatives |
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
-
1998
- 1998-12-21 US US09/217,538 patent/US6087383A/en not_active Expired - Lifetime
- 1998-12-22 JP JP2000540121A patent/JP4860037B2/ja not_active Expired - Lifetime
- 1998-12-22 ES ES98964878T patent/ES2178300T3/es not_active Expired - Lifetime
- 1998-12-22 PL PL342019A patent/PL190744B1/pl unknown
- 1998-12-22 BR BR9814736-6A patent/BR9814736A/pt not_active Application Discontinuation
- 1998-12-22 TR TR2000/01876T patent/TR200001876T2/xx unknown
- 1998-12-22 RU RU2000119792/04A patent/RU2186070C2/ru active
- 1998-12-22 CA CA002317736A patent/CA2317736C/en not_active Expired - Lifetime
- 1998-12-22 AU AU20101/99A patent/AU735875B2/en not_active Expired
- 1998-12-22 GE GEAP19985466A patent/GEP20033026B/en unknown
- 1998-12-22 CN CN98812741A patent/CN1116282C/zh not_active Expired - Lifetime
- 1998-12-22 EP EP98964878A patent/EP1056722B1/en not_active Expired - Lifetime
- 1998-12-22 IL IL13738498A patent/IL137384A0/xx active IP Right Grant
- 1998-12-22 PT PT98964878T patent/PT1056722E/pt unknown
- 1998-12-22 DK DK98964878T patent/DK1056722T3/da active
- 1998-12-22 EE EEP200000798A patent/EE04434B1/xx unknown
- 1998-12-22 HU HU0101389A patent/HU227196B1/hu unknown
- 1998-12-22 WO PCT/US1998/027382 patent/WO1999036404A1/en active IP Right Grant
- 1998-12-22 DE DE69806067T patent/DE69806067T2/de not_active Expired - Lifetime
- 1998-12-22 KR KR1020007007885A patent/KR100559283B1/ko not_active IP Right Cessation
- 1998-12-22 RO ROA200000717A patent/RO118869B1/ro unknown
- 1998-12-22 AT AT98964878T patent/ATE219057T1/de active
- 1998-12-22 SK SK1062-2000A patent/SK283975B6/sk not_active IP Right Cessation
- 1998-12-22 NZ NZ504417A patent/NZ504417A/en not_active IP Right Cessation
- 1998-12-22 UA UA2000084931A patent/UA59432C2/uk unknown
- 1998-12-22 CZ CZ20002564A patent/CZ293507B6/cs not_active IP Right Cessation
-
1999
- 1999-01-05 MY MYPI99000020A patent/MY114838A/en unknown
- 1999-01-05 ZA ZA9900056A patent/ZA9956B/xx unknown
- 1999-01-12 UY UY25345A patent/UY25345A1/es not_active Application Discontinuation
- 1999-01-15 TW TW088100623A patent/TW531531B/zh not_active IP Right Cessation
- 1999-01-17 EG EG5699A patent/EG23936A/xx active
- 1999-01-18 AR ARP990100179A patent/AR014417A1/es active IP Right Grant
- 1999-01-19 CO CO99002578A patent/CO4970820A1/es unknown
- 1999-01-20 PE PE1999000047A patent/PE20000185A1/es not_active IP Right Cessation
-
2000
- 2000-06-06 LV LVP-00-78A patent/LV12522B/en unknown
- 2000-07-14 LT LT2000067A patent/LT4780B/lt not_active IP Right Cessation
- 2000-07-17 BG BG104618A patent/BG64774B1/bg unknown
- 2000-07-19 IL IL137384A patent/IL137384A/en not_active IP Right Cessation
- 2000-07-19 NO NO20003692A patent/NO315605B1/no not_active IP Right Cessation
-
2001
- 2001-04-26 HK HK01103011A patent/HK1033667A1/xx not_active IP Right Cessation
- 2001-06-15 HK HK01104126A patent/HK1033458A1/xx not_active IP Right Cessation
-
2008
- 2008-12-17 JP JP2008321240A patent/JP2009102357A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1056722T3 (da) | Hydrogensulfatsalt af HIV-protease-inhibitor | |
| DK1064298T3 (da) | Inhibitorer af caspaser | |
| CY2004011I1 (el) | Aσυμμετρη συνθεση της πρεγαβαλινης | |
| DK1086076T3 (da) | Sulfonamidinhibitorer af aspartylprotease | |
| DK1087976T3 (da) | Polymorf form af clopidogrel-hydrogensulfat | |
| IS4928A (is) | Fosfín tengdir tálmar af grindar málmpróteösum | |
| DK1049662T3 (da) | Inhibitorer af alpha4-medieret celleadhæsion | |
| NO20013850D0 (no) | Sulfamat hydroksansyremetallproteaseinhibitor | |
| DK1686113T3 (da) | Inhibitorer af aspartylprotease | |
| NO20031869D0 (no) | Antiinflammatoriske midler | |
| DK1107980T3 (da) | Krystallinske former af EtO2C-CH2-(R)Cgl-Aze-Pab-OH | |
| DK1458447T3 (da) | Kombination af cytokrom-p450-beroende proteasinhibitorer | |
| ID23610A (id) | Alat penggeseran yang dapat dikembungkan | |
| DK1066276T3 (da) | Fremgangsmåde til syntese af HIV protease inhibitor | |
| ID28032A (id) | TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2 | |
| DK1102747T3 (da) | Krystalformer af osenetant | |
| IS6620A (is) | Nýr fjölgervingur V af tórasemíði | |
| DK0980241T3 (da) | Gelatineindkapslede opløsningsdosisformer af sertralin | |
| EE200100017A (et) | N-tert-butüülhüdroksüülamiini uued soolad | |
| DK0967202T3 (da) | Fotolyse af 7-dehydrocholesterol | |
| EE200100381A (et) | Morfolinobensamiidi uued soolad | |
| DK1088010T3 (da) | Fremstilling af polyolefiner | |
| MA26840A1 (fr) | Cristaux d'inhibiteur d'echangeur sodium-hydrogene de type 1 | |
| IS5240A (is) | Súlfatsalt af HIV próteasa lata sem hefur bætta upptöku um munn og líffræðilega upptöku | |
| DK1016404T3 (da) | Vandigt præparat af beta-caroten |